Evidence map›Paper›PMID 33370366›Full record

ArticlePloS one2020

COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study.

Simone Lanini, Chiara Montaldo, Emanuele Nicastri, Francesco Vairo, Chiara Agrati, Nicola Petrosillo, Paola Scognamiglio, Andrea Antinori, Vincenzo Puro, Antonino Di Caro and 14 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Red Blood Cell Distribution Width Is Not a Predictor of Hospital Mortality in Elderly and Nonelderly COVID-19-Infected Patients: A Prospective Study at a Brazilian Quaternary University Hospital.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. CBC Differences between Survived and Deceased COVID-19 Patients: A Cohort Study.Medical journal of the Islamic Republic of Iran · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 5 countries.

Simone LaniniNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.ORCID 0000-0002-6743-4001
Chiara MontaldoNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.ORCID 0000-0001-7346-7507
Emanuele NicastriNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Francesco VairoNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Chiara AgratiNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Nicola PetrosilloNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Paola ScognamiglioNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Andrea AntinoriNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Vincenzo PuroNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Antonino Di CaroNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.ORCID 0000-0001-6027-3009
Gabriella De CarliNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Assunta NavarraNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Alessandro AgrestaNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Claudia CimagliaNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Fabrizio PalmieriNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Gianpiero D'OffiziNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Luisa MarchioniNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Gary Pignac KobingerCentre de Recherche en Infectiologie de l'Université Laval, Quebec City, QC, Canada.
Markus MaeurerChampalimaud Centre for the Unknown, Lisbon, Portugal.
Enrico GirardiNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Maria Rosaria CapobianchiNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Alimuddin ZumlaDepartment of Infection, Division of Infection and Immunity, University College London, London, United Kingdom.
Franco LocatelliDepartment of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Giuseppe IppolitoNational Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy.
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · ITBambino Gesù Children's Hospital · ITChampalimaud Foundation · PTEast London NHS Foundation Trust · GBUniversité Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetailed temporal analyses of complete (full) blood count (CBC) parameters, their evolution and relationship to patient age, gender, co-morbidities and management outcomes in survivors and non-survivors with COVID-19 disease, could identify prognostic clinical biomarkers.

methodsFrom 29 January 2020 until 28 March 2020, we performed a longitudinal cohort study of COVID-19 inpatients at the Italian National Institute for Infectious Diseases, Rome, Italy. 9 CBC parameters were studied as continuous variables [neutrophils, lymphocytes, monocytes, platelets, mean platelet volume, red blood cell count, haemoglobin concentration, mean red blood cell volume and red blood cell distribution width (RDW %)]. Model-based punctual estimates, as average of all patients' values, and differences between survivors and non-survivors, overall, and by co-morbidities, at specific times after symptoms, with relative 95% CI and P-values, were obtained by marginal prediction and ANOVA- style joint tests. All analyses were carried out by STATA 15 statistical package. MAIN

findings379 COVID-19 patients [273 (72% were male; mean age was 61.67 (SD 15.60)] were enrolled and 1,805 measures per parameter were analysed. Neutrophils' counts were on average significantly higher in non-survivors than in survivors (P<0.001) and lymphocytes were on average higher in survivors (P<0.001). These differences were time dependent. Average platelets' counts (P<0.001) and median platelets' volume (P<0.001) were significantly different in survivors and non-survivors. The differences were time dependent and consistent with acute inflammation followed either by recovery or by death. Anaemia with anisocytosis was observed in the later phase of COVID-19 disease in non-survivors only. Mortality was significantly higher in patients with diabetes (OR = 3.28; 95%CI 1.51-7.13; p = 0.005), obesity (OR = 3.89; 95%CI 1.51-10.04; p = 0.010), chronic renal failure (OR = 9.23; 95%CI 3.49-24.36; p = 0.001), COPD (OR = 2.47; 95% IC 1.13-5.43; p = 0.033), cardiovascular diseases (OR = 4.46; 95%CI 2.25-8.86; p = 0.001), and those >60 years (OR = 4.21; 95%CI 1.82-9.77; p = 0.001). Age (OR = 2.59; 95%CI 1.04-6.45; p = 0.042), obesity (OR = 5.13; 95%CI 1.81-14.50; p = 0.002), renal chronic failure (OR = 5.20; 95%CI 1.80-14.97; p = 0.002) and cardiovascular diseases (OR 2.79; 95%CI 1.29-6.03; p = 0.009) were independently associated with poor clinical outcome at 30 days after symptoms' onset.

interpretationIncreased neutrophil counts, reduced lymphocyte counts, increased median platelet volume and anaemia with anisocytosis, are poor prognostic indicators for COVID19, after adjusting for the confounding effect of obesity, chronic renal failure, COPD, cardiovascular diseases and age >60 years.

Indexed as

BiomarkersBlood Cell CountCohort StudiesCOVID-19DemographyErythrocyte IndicesFemaleHumansInflammationLeukocyte CountLongitudinal StudiesLymphocytesMaleMean Platelet VolumeMiddle AgedNeutrophilsBiomarkers

Identifiers

PMID33370366
PMCPMC7769441
OpenAlexW3112441150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.